Jiangsu Hengrui Pharmaceuticals (600276.SH) has submitted an application to the Hong Kong Stock Exchange for the issuance and listing of H shares.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has submitted an application to the Hong Kong Stock Exchange on January 6, 2025 to issue overseas listed foreign shares (H shares) and list on the main board of the Hong Kong Stock Exchange. On the same day, the company published the application materials on the Hong Kong Stock Exchange website. The application materials were prepared and published in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, and are a draft version. The information contained in the materials may be updated and changed as necessary.